Gilead Sciences stories

Gilead Sciences and Merck's Once-Weekly HIV Pill Maintains Viral Suppression in Phase 3 Trials

Gilead Sciences and Merck announced that their experimental once-weekly HIV pill combining islatravir and lenacapavir successfully maintained viral suppression at 48 weeks in two Phase 3 trials (ISLEND-1 and ISLEND-2) involving 1,209 adults with virologically suppressed HIV. The results support regulatory filings for what could become the first once-weekly oral HIV treatment regimen.